Aligos Therapeutics (ALGS) Research & Development (2019 - 2026)

Aligos Therapeutics (ALGS) has reported Research & Development for 8 consecutive years, with $24.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development rose 72.08% year-over-year to $24.0 million; the trailing twelve-month figure through Jun 2026 stood at $88.4 million (up 44.21% YoY), and the FY2025 full-year result was $69.5 million, down 1.16% from the prior year.
• Research & Development improved to $24.0 million in Q2 2026 per ALGS's latest filing, from $23.4 million in the prior quarter.
• Across five years, Research & Development topped out at $31.7 million in Q1 2022 and bottomed at $14.0 million in Q2 2025.
• Historically, Research & Development has averaged $19.2 million across 5 years, with a median of $17.4 million in 2022.
• The sharpest annual moves came in 2023 and 2026: Research & Development sank 42.75% in 2023, then jumped 72.08% in 2026.
• Over 5 years, Research & Development stood at $19.1 million in 2022, then increased by 16.53% to $22.3 million in 2023, then retreated by 27.97% to $16.0 million in 2024, then rose by 6.28% to $17.0 million in 2025, then soared by 41.16% to $24.0 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $24.0 million, $23.4 million, and $17.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.